Patents by Inventor Kaixian Chen

Kaixian Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190135818
    Abstract: The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.
    Type: Application
    Filed: May 24, 2017
    Publication date: May 9, 2019
    Inventors: Hualiang JIANG, Hong LIU, Meiyu GENG, Mingyue ZHENG, Jing AI, Yulan WANG, Xiaowei WU, Shuangjie LI, Xia PENG, Chunpu LI, Kaixian CHEN, Bao WANG
  • Publication number: 20190100529
    Abstract: The invention describes a polymorph of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid maleate and a preparation method therefor. The polymorph is a crystal having high stability and low hygroscopicity, and the crystal form is selected from crystal form A, crystal form B and crystal form C. Furthermore, the crystal form has a strong in-vivo hypoglycemic activity and can be used for the preparation of a novel drug for the treatment or prevention of diabetes mellitus type H and/or complications of diabetes mellitus type H.
    Type: Application
    Filed: March 20, 2017
    Publication date: April 4, 2019
    Inventors: Hong LIU, Jiang WANG, Jian LI, Jia LI, Jingya LI, Hualiang JIANG, Xiaomin LUO, Kaixian CHEN
  • Publication number: 20190100507
    Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.
    Type: Application
    Filed: March 16, 2017
    Publication date: April 4, 2019
    Inventors: Hong LIU, Jia LI, Jiang WANG, Mingbo SU, Shuni WANG, Yubo ZHOU, Wei ZHU, Wei XU, Chunpu LI, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20190031678
    Abstract: The invention relates to a salt form of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid and a preparation method for the salt form. Also disclosed is a pharmaceutical composition of the formula I compound salt form.
    Type: Application
    Filed: March 22, 2017
    Publication date: January 31, 2019
    Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong LIU, Jiang WANG, Jian LI, Jia LI, Jingya LI, Hualiang JIANG, Xiaomin LUO, Kaixian CHEN
  • Patent number: 10167299
    Abstract: Provided are 1-(3-aminopropyl) substituted cyclic amine compounds as represented by frmula (I), pharmaceutically acceptable salts, enantiomers, diastereoisomers, racemates and mixtures thereof, and a method of synthesizing said 1-(3-aminopropyl) substituted cyclic amine compounds by using aromatic heterocyclic formaldehyde as raw material. Said compounds can be used as CCR 5 antagonist for the treatment of HIV infection.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 1, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Beili Wu, Yongtang Zheng, Xin Xie, Hualiang Jiang, Panfeng Peng, Ronghua Luo, Jing Li, Jian Li, Ya Zhu, Ying Chen, Haonan Zhang, Liumeng Yang, Yu Zhou, Kaixian Chen
  • Publication number: 20180305390
    Abstract: C, O-spiro aryl glycoside compounds are provided. Specifically provided are C, O-spiro aryl glycoside compounds represented by the formula (I), wherein the definitions of each variable group are described in the specification. Also provided are methods of preparing and using the C, O-spiro aryl glycoside compounds. The C, O-spiro aryl glycoside compounds can be used as SGLT2 inhibitors and for treating diseases, such as diabetes, atherosclerosis, and adiposity.
    Type: Application
    Filed: June 23, 2016
    Publication date: October 25, 2018
    Inventors: Hong LIU, Jia LI, Jiang WANG, Jingya LI, Hui CHEN, Dan LI, Jian LI, Yibing WANG, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20180194767
    Abstract: Compounds of formula I are provided. Also provided are methods of preparing the compounds of formula (I), and methods of using the compounds of formula (I) as a negative allosteric modulator of a metabotropic glutamate receptor (mGluR) subtype 5.
    Type: Application
    Filed: April 15, 2016
    Publication date: July 12, 2018
    Inventors: Hong LIU, Yu ZHOU, Dong ZHANG, Jian LI, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20180030066
    Abstract: The present invention relates to crystal form A of a compound. The present invention also discloses a preparation method and a pharmaceutical composition of the crystal form A. The crystal form A has strong hypoglycemic activity in vivo and is expected to be a novel pharmaceutically active ingredient for treating or preventing type II diabetes and/or complications of type II diabetes.
    Type: Application
    Filed: February 3, 2016
    Publication date: February 1, 2018
    Inventors: Hong LIU, Jian WANG, Jian LI, Jia LI, Jingya LI, Shengbin ZHOU, Mingbo SU, Hualiang JIANG, Xiaomin LUO, Kaixian CHEN
  • Patent number: 9868716
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 16, 2018
    Assignees: HONG KONG BAPTIST UNIVERSITY, SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE
    Inventors: Hongxi Xu, Yue Lv, Wenwei Fu, Kaixian Chen, Zhaoxiang Bian, Shilin Chen, Dajian Yang, Aiping Lu, Sun Chi Albert Chan
  • Patent number: 9751882
    Abstract: The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: September 5, 2017
    Assignee: Kingsound & Partner
    Inventors: Hong Liu, Xuechu Zhen, Haifeng Sun, Liyuan Zhu, Wangke Qian, Leiping Yu, Zeng Li, Shengbin Zhou, Wenxian Cai, Hualiang Jiang, Kaixian Chen
  • Patent number: 9737517
    Abstract: Use of hexahydro-dibenzo[a,g]quinolizine compounds as shown in formula(I) in preparing a medicine for treating and/or preventing benign prostate hyperplasia diseases.
    Type: Grant
    Filed: May 4, 2014
    Date of Patent: August 22, 2017
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Xin Xie, Haifeng Sun, Jing Li, Fei Zhao, Ying Chen, Zeng Li, Yu Zhou, Hualiang Jiang, Kaixian Chen
  • Patent number: 9637454
    Abstract: The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular to compounds of general formula I, racemates, R-isomers, S-isomers, and pharmaceutically acceptable salts thereof and their mixtures, and the preparation methods thereof and a pharmaceutical composition containing the compounds and uses thereof as an acetylcholine esterase inhibitor.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 2, 2017
    Assignee: SHANGHAI INSTITUTE OF MATERIA MADICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Haiyan Zhang, Yu Zhou, Yan Fu, Hualiang Jiang, Xican Tang, Kaixian Chen
  • Publication number: 20170087173
    Abstract: Disclosed is a Glechoma longituba (Nakai) Kupr. extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.
    Type: Application
    Filed: March 17, 2015
    Publication date: March 30, 2017
    Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES, NANJING PAILEXING PHARMACEUTICAL TECHNOLOGY LTD.
    Inventors: Weiliang ZHU, Heyao WANG, Yong ZHANG, Peng SUN, Bo LI, Zhijian XU, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20170044187
    Abstract: Provided are 1-(3-aminopropyl) substituted cyclic amine compounds as represented by formula (I), pharmaceutically acceptable salts, enantiomers, diastereoisomers, racemates and mixtures thereof, and a method of synthesizing said 1-(3-aminopropyl) substituted cyclic amine compounds by using aromatic heterocyclic formaldehyde as raw material. Said compounds can be used as CCR 5 antagonist for the treatment of HIV infection.
    Type: Application
    Filed: December 29, 2014
    Publication date: February 16, 2017
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong LIU, Beili WU, Yongtang ZHENG, Xin XIE, Hualiang JIANG, Panfeng PENG, Ronghua LUO, Jing LI, Jian LI, Ya ZHU, Ying CHEN, Haonan ZHANG, Liumeng YANG, Yu ZHOU, Kaixian CHEN
  • Publication number: 20170035824
    Abstract: Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 9, 2017
    Inventors: Hongxi XU, Yuanzhi LAO, Hongsheng TAN, Naihan XU, Xiaoyu WANG, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Patent number: 9408811
    Abstract: Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound of formula (I): More particularly, it relates to said anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 9, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Hongxi Xu, Xin Li, Hong Zhang, Yuanzhi Lao, Hongsheng Tan, Xiaoyu Wang, Kaixian Chen, Zhaoxiang Bian, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20160193195
    Abstract: Use of hexahydro-dibenzo[a,g]quinolizine compounds as shown in formula(I) in preparing a medicine for treating and/or preventing benign prostate hyperplasia diseases.
    Type: Application
    Filed: May 4, 2014
    Publication date: July 7, 2016
    Inventors: Hong LIU, Xin XIE, Haifeng SUN, Jing LI, Fei ZHAO, Ying CHEN, Zeng LI, Yu ZHOU, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20160185744
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,
    Type: Application
    Filed: August 12, 2015
    Publication date: June 30, 2016
    Inventors: Hongxi XU, Yue LV, Wenwei FU, Kaixian CHEN, Zhaoxiang BIAN, Shilin CHEN, Dajian YANG, Aiping LU, Sun Chi Albert CHAN
  • Patent number: 9359372
    Abstract: The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: June 7, 2016
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Xin Xie, Xuechu Zhen, Haifeng Sun, Jing Li, Liyuan Zhu, Zeng Li, Ying Chen, Hualiang Jiang, Kaixian Chen
  • Patent number: 9339488
    Abstract: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: May 17, 2016
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Hongxi Xu, Hong Zhang, Yuanzhi Lao, Xiaoyu Wang, Kaixian Chen, Dajian Yang, Shilin Chen, Chengyuan Lin, Zhaoxiang Bian, Aiping Lu, Albert Sun Chi Chan